Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Current Assets (2016 - 2026)

Ekso Bionics Holdings has reported Current Assets over the past 13 years, most recently at $14.0 million for Q4 2025.

  • On a quarterly basis, Current Assets fell 25.44% to $14.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $14.0 million, a 25.44% decrease, with the full-year FY2025 number at $14.0 million, down 25.44% from a year prior.
  • Current Assets reached $14.0 million in Q4 2025 per EKSO's latest filing, down from $14.8 million in the prior quarter.
  • The five-year high for Current Assets was $54.6 million in Q1 2021, with the low at $14.0 million in Q4 2025.
  • The 5-year median for Current Assets is $23.5 million (2023), against an average of $29.6 million.
  • Peak YoY movement for Current Assets: surged 288.32% in 2021, then tumbled 39.16% in 2023.
  • Tracing EKSO's Current Assets over 5 years: stood at $47.8 million in 2021, then crashed by 35.06% to $31.0 million in 2022, then crashed by 34.89% to $20.2 million in 2023, then fell by 6.75% to $18.8 million in 2024, then decreased by 25.44% to $14.0 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $14.0 million, $14.8 million, and $16.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.